Stocks On the Move: iRobot Corporation, Regulus Therapeutics Inc, and Tekmira Pharmaceuticals Corporation

IRBT, RGLS, and TKMR are moving sharply in Wednesday's trading

Oct 22, 2014 at 11:25 AM
facebook X logo linkedin


U.S. stocks are modestly higher this morning, as Wall Street digests stimulus news out of Europe, a slight uptick in consumer prices, and the latest round of earnings reports. Among the names making significant moves are artificial intelligence issue iRobot Corporation (NASDAQ:IRBT), as well as drugmakers Regulus Therapeutics Inc (NASDAQ:RGLS) and Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR). Here's a quick look at how IRBT, RGLS, and TKMR are faring on the charts today.

  • IRBT is 16.6% higher at $36.87, after the firm said third-quarter profit nearly doubled from the year-ago period, topping analysts' expectations. The shares of iRobot Corporation are now 5.3% higher year-to-date, and on pace to end the week atop their 10-week and 20-week moving averages for the first time since early July. J.P. Morgan Securities chimed in by upping its price target to $38 from $36.50, though the brokerage firm upheld a lukewarm "neutral" rating. Elsewhere, short sellers could be hitting the bricks. Short interest accounts for more than a quarter of IRBT's total available float, representing nearly nine sessions' worth of pent-up buying demand, at the stock's average pace of trading.

  • RGLS is hands-down the biggest advancer on the Nasdaq thus far, after the firm announced encouraging data regarding its proposed hepatitis C treatment. The stock was last seen 84.6% higher at $12.50, and earlier peaked at a record high of $15 -- more than twice the stock's closing price of $6.77 yesterday. As with IRBT, Regulus Therapeutics Inc shares are likely enjoying a short squeeze, as short interest accounts for 8.1% of the equity's available float. In fact, it would take more than three weeks to buy back all of these bearish bets, at RGLS' average daily trading volume.

  • TKMR is flirting with $19.69, up 9.8%, after the company said it's started limited manufacturing of an Ebola treatment, which should be available by early December. On the charts, TKMR has skyrocketed 147% year-to-date, but since grazing the $30 level earlier this month, has dropped to test support at its 80-day moving average. Most analysts are already in the bulls' camp, with four out of six offering up "buy" or better endorsements, and not a single "sell" in sight. Plus, the consensus 12-month price target of $36.50 stands in uncharted territory for Tekmira Pharmaceuticals Corporation, and represents expected upside of more than 85% to the stock's current price.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI